3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Gynecologic
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Radiotherapy
64
Temozolomide
59
Vincristine
33
Cyclophosphamide
32
Carboplatin
30
Radiosurgery
26
Etoposide
25
Cisplatin
25
Lomustine
24
Magnetic Resonance Spectroscopy
19
Filgrastim
17
Doxorubicin
15
Bevacizumab
15
Radiation
13
Specimen Handling
12
Granulocyte Colony-Stimulating Factor
12
Surgical Procedures, Operative
11
Isotretinoin
11
Melphalan
10
Carmustine
10
Procarbazine
9
Platinum
9
Peripheral Blood Stem Cell Transplantation
9
Chemotherapy, Adjuvant
9
etoposide phosphate
7
Topotecan
7
1,2-diaminocyclohexaneplatinum II citrate
7
sargramostim
6
Thiotepa
6
Radiotherapy, Intensity-Modulated
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Mebendazole
×
CNS
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn